I<sub>2</sub>/TBHP-Mediated Oxidative Coupling of Amino-Based Bisnucleophiles and Isocyanides: Access to 2-Aminobenzoxazinones, 2-Aminobenzoxazines, and 2-Aminoquinazolines under Metal-Free Conditions
作者:Hong-Xia Wang、Tian-Qi Wei、Pei Xu、Shun-Yi Wang、Shun-Jun Ji
DOI:10.1021/acs.joc.8b02395
日期:2018.11.2
An I2/tert-butyl hydroperoxide (TBHP)-mediated oxidative coupling reaction of isocyanides with amino-based bisnucleophiles is described for the synthesis of 2-aminobenzoxazinones, 2-aminobenzoxazines, and 2-aminoquinozolines in moderate to excellent yields. Furthermore, this method provides a simple and practical method to construct potential functionalized biologically active molecules.
In the presence of the [Cp*IrCl2]2/NaOH system, the direct N-alkylation of 2-aminoquinazolines and 2-aminopyrimidines with alcohols afforded the N-exosubstituted 2-(N-alkylamino)quinazolines and 2-(N-alkylamino)pyrimidines with 71–96% yields and complete regioselectivities. The protocol is highly attractive because of easily available starting materials, high atom efficiency and environmental friendliness
Nucleophilic aromatic substitution of heterocycles using a high-temperature and high-pressure flow reactor
作者:Manwika Charaschanya、Andrew R. Bogdan、Ying Wang、Stevan W. Djuric
DOI:10.1016/j.tetlet.2016.01.080
日期:2016.3
nucleophiles. Utilizing the Phoenix Flow Reactor™ in parallel with Design-of-Experiment software enabled rapid optimization of the SNAr protocol. This protocol facilitated efficient synthesis of a broad range of 2-aminoquinazolines, and was extended to 2-aminoquinoxalines and 2-aminobenzimidazoles.
我们在此报告的高温和高压的连续流协议来进行亲核芳香取代(S Ñ与氮亲核试剂的杂环的Ar)。通过将Phoenix Flow Reactor™与实验设计软件并行使用,可以快速优化S N Ar协议。该协议促进了广泛范围的2-氨基喹唑啉的有效合成,并扩展到2-氨基喹喔啉和2-氨基苯并咪唑。
SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS
申请人:Huang Liming
公开号:US20100056506A1
公开(公告)日:2010-03-04
The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein: R
1
, R
2
, Z
1
, t, and ring A are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of JNK, such as diabetes, the method comprising administering to a mammal an effective amount of a compound of formula (I).